• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多发性硬化症复发的诊断与治疗建议。

Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses.

作者信息

Ramo-Tello Cristina, Blanco Yolanda, Brieva Luis, Casanova Bonaventura, Martínez-Cáceres Eva, Ontaneda Daniel, Ramió-Torrentá Lluís, Rovira Àlex

机构信息

Multiple Sclerosis and Clinical Neuroimmunology Unit, Germans Trias University Hospital, 08916 Badalona, Spain.

Multiple Sclerosis Unit, Clínic Hospital, 08036 Barcelona, Spain.

出版信息

J Pers Med. 2021 Dec 22;12(1):6. doi: 10.3390/jpm12010006.

DOI:10.3390/jpm12010006
PMID:35055321
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8780774/
Abstract

Minimizing the risk of relapse is essential in multiple sclerosis (MS). As none of the treatments currently available are capable of completely preventing relapses, treatment of these episodes remains a cornerstone of MS care. The objective of this manuscript is to reduce uncertainty and improve quality of care of this neurological process. This article addresses definitions of key concepts, recommendations for clinical examination, classification criteria, magnetic resonance imaging, biomarkers, and specific therapeutic counsels including special populations such as pregnant and breastfeeding women, and children. An algorithm for treating MS relapses is also provided.

摘要

在多发性硬化症(MS)中,将复发风险降至最低至关重要。由于目前可用的治疗方法均无法完全预防复发,因此对这些发作的治疗仍然是MS护理的基石。本手稿的目的是减少不确定性并提高对这一神经过程的护理质量。本文阐述了关键概念的定义、临床检查建议、分类标准、磁共振成像、生物标志物以及包括孕妇、哺乳期妇女和儿童等特殊人群在内的特定治疗建议。还提供了一种治疗MS复发的算法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0c6/8780774/f6699b1f749f/jpm-12-00006-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0c6/8780774/f6699b1f749f/jpm-12-00006-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0c6/8780774/f6699b1f749f/jpm-12-00006-g001.jpg

相似文献

1
Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses.多发性硬化症复发的诊断与治疗建议。
J Pers Med. 2021 Dec 22;12(1):6. doi: 10.3390/jpm12010006.
2
Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.口服与静脉注射类固醇治疗多发性硬化症复发的比较
Cochrane Database Syst Rev. 2012 Dec 12;12:CD006921. doi: 10.1002/14651858.CD006921.pub3.
3
Mitoxantrone: a review of its use in multiple sclerosis.米托蒽醌:其在多发性硬化症中的应用综述
CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010.
4
Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.口服与静脉注射类固醇治疗多发性硬化症复发的疗效比较
Cochrane Database Syst Rev. 2009 Jul 8(3):CD006921. doi: 10.1002/14651858.CD006921.pub2.
5
Association Between Breastfeeding and Postpartum Multiple Sclerosis Relapses: A Systematic Review and Meta-analysis.母乳喂养与产后多发性硬化症复发的关联:系统评价和荟萃分析。
JAMA Neurol. 2020 Mar 1;77(3):327-338. doi: 10.1001/jamaneurol.2019.4173.
6
EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses.欧洲神经病学学会多发性硬化复发治疗指南:欧洲神经病学学会多发性硬化复发治疗特别工作组报告
Eur J Neurol. 2005 Dec;12(12):939-46. doi: 10.1111/j.1468-1331.2005.01352.x.
7
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.用于多发性硬化症的免疫调节剂和免疫抑制剂:一项网状Meta分析
Cochrane Database Syst Rev. 2013 Jun 6;2013(6):CD008933. doi: 10.1002/14651858.CD008933.pub2.
8
Acute Multiple Sclerosis Relapse.急性多发性硬化症复发
Continuum (Minneap Minn). 2016 Jun;22(3):799-814. doi: 10.1212/CON.0000000000000330.
9
Therapeutic management of severe relapses in multiple sclerosis.多发性硬化严重复发的治疗管理。
Curr Treat Options Neurol. 2015 Apr;17(4):345. doi: 10.1007/s11940-015-0345-6.
10
Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey.复发率、症状和医疗保健参与度:来自 2017 年美国多发性硬化症调查的患者见解。
Mult Scler Relat Disord. 2018 Nov;26:219-234. doi: 10.1016/j.msard.2018.09.002. Epub 2018 Sep 7.

引用本文的文献

1
Exploring the Clinical Utility of Neurofilament Light Chain Assays in Multiple Sclerosis Management.探索神经丝轻链检测在多发性硬化症管理中的临床应用价值。
Neurol Neuroimmunol Neuroinflamm. 2025 Jul;12(4):e200427. doi: 10.1212/NXI.0000000000200427. Epub 2025 Jun 18.
2
Infection, Relapses, and Pseudo-Relapses in Individuals With Multiple Sclerosis.多发性硬化症患者的感染、复发及假性复发
Neurol Clin Pract. 2025 Aug;15(4):e200493. doi: 10.1212/CPJ.0000000000200493. Epub 2025 Jun 4.
3
Plasma Exchange vs. Immunoadsorption: Effects on Immunological Markers and Predictive Value in Steroid-Refractory MS Attacks.

本文引用的文献

1
Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach.用于多发性硬化症临床复发的客观生物标志物:一种代谢组学方法。
Brain Commun. 2021 Oct 12;3(4):fcab240. doi: 10.1093/braincomms/fcab240. eCollection 2021.
2
Increased Serum Neurofilament Light and Thin Ganglion Cell-Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis.血清神经丝轻链和薄髓鞘内丛状层增高是早期多发性硬化疾病活动的附加危险因素。
Neurol Neuroimmunol Neuroinflamm. 2021 Aug 4;8(5). doi: 10.1212/NXI.0000000000001051. Print 2021 Sep.
3
Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy.
血浆置换与免疫吸附:对类固醇难治性多发性硬化发作中免疫标志物的影响及预测价值
Mult Scler J Exp Transl Clin. 2025 Apr 15;11(2):20552173251321797. doi: 10.1177/20552173251321797. eCollection 2025 Apr-Jun.
4
Advancements in multiple sclerosis.多发性硬化症的进展
Intern Med J. 2025 Jun;55(6):895-904. doi: 10.1111/imj.70023. Epub 2025 Apr 2.
5
Liver Injury Following Intravenous Methylprednisolone Pulse Therapy in Multiple Sclerosis: The Experience from a Single Academic Liver Center.多发性硬化症患者静脉注射甲基泼尼松龙冲击治疗后的肝损伤:来自单一学术性肝病中心的经验
Biomolecules. 2025 Mar 19;15(3):437. doi: 10.3390/biom15030437.
6
New diagnosis of multiple sclerosis in the setting of recent Sinopharm COVID-19 vaccine (BBIBP-CorV) exposure: A series of clinical cases and updated review of the literature.近期接种国药新冠疫苗(BBIBP-CorV)后新发多发性硬化症:一系列临床病例及文献综述更新
Curr J Neurol. 2024 Jan 5;23(1):21-38. doi: 10.18502/cjn.v23i1.16430.
7
Potential Application of Plant-Derived Compounds in Multiple Sclerosis Management.植物源化合物在多发性硬化症治疗中的潜在应用。
Nutrients. 2024 Sep 5;16(17):2996. doi: 10.3390/nu16172996.
8
Corticosteroid-depending effects on peripheral immune cell subsets vary according to disease modifying strategies in multiple sclerosis.皮质类固醇对多发性硬化症中不同疾病修正策略的外周免疫细胞亚群的影响不同。
Front Immunol. 2024 Jun 13;15:1404316. doi: 10.3389/fimmu.2024.1404316. eCollection 2024.
9
Serum neurofilament light chain and glial fibrillary acidic protein for predicting response to apheresis in steroid-refractory multiple sclerosis relapses.血清神经丝轻链和胶质纤维酸性蛋白预测激素难治性多发性硬化复发患者对血浆置换的反应。
Eur J Neurol. 2024 Aug;31(8):e16323. doi: 10.1111/ene.16323. Epub 2024 May 3.
10
Genetic susceptibility and causal pathway analysis of eye disorders coexisting in multiple sclerosis.多发性硬化症中共存眼部疾病的遗传易感性和因果途径分析。
Front Immunol. 2024 Feb 5;15:1337528. doi: 10.3389/fimmu.2024.1337528. eCollection 2024.
为多发性硬化症的有效治疗铺平道路:细胞疗法的进展。
Cell Mol Immunol. 2021 Jun;18(6):1353-1374. doi: 10.1038/s41423-020-00618-z. Epub 2021 May 6.
4
COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?COVID-19 与多发性硬化症患者的复发风险:一场没有旁观者效应的战斗?
Mult Scler Relat Disord. 2021 Jun;51:102915. doi: 10.1016/j.msard.2021.102915. Epub 2021 Mar 20.
5
An asymptomatic new lesion on MRI is a relapse and should be treated accordingly - Commentary.MRI上出现的无症状新病灶即复发,应相应进行治疗——评论
Mult Scler. 2019 Dec;25(14):1845-1847. doi: 10.1177/1352458519885110. Epub 2019 Nov 1.
6
An asymptomatic new lesion on MRI is a relapse and should be treated accordingly - No.MRI上无症状的新病灶是复发,应相应进行治疗——错误。
Mult Scler. 2019 Dec;25(14):1843-1845. doi: 10.1177/1352458519845111. Epub 2019 Nov 1.
7
An asymptomatic new lesion on MRI is a relapse and should be treated accordingly - Yes.MRI上无症状的新病灶即为复发,应相应进行治疗——是。
Mult Scler. 2019 Dec;25(14):1842-1843. doi: 10.1177/1352458519855723. Epub 2019 Nov 1.
8
Improving Outcomes in Pediatric Multiple Sclerosis: Current and Emerging Treatments.改善小儿多发性硬化症的预后:现有和新兴治疗方法。
Paediatr Drugs. 2019 Jun;21(3):137-152. doi: 10.1007/s40272-019-00338-6.
9
Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study.利妥昔单抗治疗多发性硬化症的安全性和疗效:一项回顾性观察研究。
J Immunol Res. 2018 Nov 12;2018:9084759. doi: 10.1155/2018/9084759. eCollection 2018.
10
Comparison of two high doses of oral methylprednisolone for multiple sclerosis relapses: a pilot, multicentre, randomized, double-blind, non-inferiority trial.两种大剂量口服甲泼尼龙治疗多发性硬化症复发的比较:一项先导、多中心、随机、双盲、非劣效性试验。
Eur J Neurol. 2019 Mar;26(3):525-532. doi: 10.1111/ene.13851. Epub 2018 Nov 16.